176 related articles for article (PubMed ID: 21155012)
21. Irinotecan in the management of patients with pancreatic cancer.
Green MR; Harper M; Safa A; Sherman CA; Mushtaq CM; Bahadori H; Brescia FJ; Rocha Lima CM
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):31-3. PubMed ID: 11200146
[TBL] [Abstract][Full Text] [Related]
22. Irinotecan in the treatment of gastric cancer.
Bugat R
Ann Oncol; 2003; 14 Suppl 2():ii37-40. PubMed ID: 12810456
[TBL] [Abstract][Full Text] [Related]
23. [Combination chemotherapy of S-1 +CPT-11 (q 4-5 w) for metastatic gastric cancer].
Sugimoto N; Narahara H
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():79-82. PubMed ID: 16897977
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.
Katsube T; Ogawa K; Ichikawa W; Fujii M; Tokunaga A; Takagi Y; Kochi M; Hayashi K; Kubota T; Aiba K; Arai K; Terashima M; Kitajima M
Anticancer Drugs; 2007 Jun; 18(5):605-10. PubMed ID: 17414630
[TBL] [Abstract][Full Text] [Related]
25. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
26. Single-agent irinotecan as second-line treatment for advanced gastric cancer.
Kanat O; Evrensel T; Manavoglu O; Demiray M; Kurt E; Gonullu G; Kiyici M; Arslan M
Tumori; 2003; 89(4):405-7. PubMed ID: 14606644
[TBL] [Abstract][Full Text] [Related]
27. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer.
Farhat FS
Med Oncol; 2007; 24(2):137-46. PubMed ID: 17848736
[TBL] [Abstract][Full Text] [Related]
28. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
Guo X; Zhao F; Ma X; Shen G; Ren D; Zheng F; Du F; Wang Z; Ahmad R; Yuan X; Zhao J; Zhao J
BMC Cancer; 2019 Nov; 19(1):1125. PubMed ID: 31747911
[TBL] [Abstract][Full Text] [Related]
29. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis.
Yang J; Zhou Y; Min K; Yao Q; Xu CN
World J Gastroenterol; 2014 Sep; 20(33):11886-93. PubMed ID: 25206296
[TBL] [Abstract][Full Text] [Related]
30. The current status of irinotecan (CPT-11) in the United States.
Rothenberg ML
Ann N Y Acad Sci; 1996 Dec; 803():272-81. PubMed ID: 8993521
[No Abstract] [Full Text] [Related]
31. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
32. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
Kakolyris S; Kouroussis C; Kalbakis K; Mavroudis D; Souglakos J; Nvardakis ; Kremos S; Georgoulias V
Ann Oncol; 2000 Jun; 11(6):757-60. PubMed ID: 10942068
[TBL] [Abstract][Full Text] [Related]
33. Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
Shimoyama S; Aoki F; Shimizu N; Tatsutomi Y; Mafune K; Kaminishi M
Int J Clin Oncol; 2003 Feb; 8(1):49-52. PubMed ID: 12601543
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer.
Luo HQ; Han L; Jiang Y
Asian Pac J Cancer Prev; 2014; 15(13):5343-8. PubMed ID: 25040999
[TBL] [Abstract][Full Text] [Related]
35. S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.
Li DH; Pan ZK; Ye F; An HX; Wu JX
Tumour Biol; 2014 Aug; 35(8):8201-8. PubMed ID: 24850178
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
Wagner AD; Grothe W; Haerting J; Kleber G; Grothey A; Fleig WE
J Clin Oncol; 2006 Jun; 24(18):2903-9. PubMed ID: 16782930
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer.
Fujitani K; Tsujinaka T; Hirao M
Oncology; 2003; 64(2):111-5. PubMed ID: 12566907
[TBL] [Abstract][Full Text] [Related]
39. [CPT-11 combined chemotherapy for metastatic gastric cancer].
Narahara H; Sugimoto N; Iishi H; Tatsuta M
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1973-7. PubMed ID: 15570923
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
Nagahori Y; Nagahori K; Hamaguchi Y; Fukushima T; Masui H; Mogaki M; Abe T
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1555-9. PubMed ID: 18799911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
